EXAS
High convictionExact Sciences Corporation
Healthcare · NASDAQ
$20.0B mkt cap
Brief updated Jun 28, 2026
Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers
Exact Sciences trades at a deep discount to intrinsic value while burning cash at a scale that demands scrutiny.
Exact Sciences dominates non-invasive colorectal cancer screening through Cologuard, its stool-DNA test with strong clinical adoption and broad insurance coverage. Revenue growth of 325% year over year signals genuine commercial momentum. However, a net margin of negative 640% and a negative price-to-earnings ratio of 95.7x reveal that growth is being purchased at an extraordinary cost. The composite conviction score of 40 out of 100 sits in high-conviction territory by this framework, yet the gap between a DCF intrinsic value of $77 and current trading levels versus the cash burn creates a thesis held in tension — the narrative is compelling, the math is punishing.
Why now
The broader market is cycling into risk-on behavior, with the Nasdaq jumping nearly 500 points on geopolitical de-escalation signals, which historically lifts high-growth, high-loss healthcare names disproportionately. At the same time, the greed index remaining in the fear zone means sentiment has not yet fully repriced Exact Sciences toward its DCF value of $77, leaving a potential rerating window open.
Key risks
A net margin of negative 640% means the company is structurally unprofitable at scale, and any deceleration in revenue growth removes the justification for the loss. Competitive risk is acute — colonoscopy reimbursement changes or a rival multi-cancer early detection test gaining Medicare coverage could compress Cologuard's addressable market faster than consensus expects. Macro tightening or a shift back to risk-off rotation would disproportionately punish a cash-burning name with no earnings floor.
What to watch
Track gross margin trajectory quarter over quarter — the reported 69.69% gross margin is the one structural positive, and any compression signals pricing or mix deterioration that would undermine the path to profitability. Watch for Medicare coverage decisions on competing multi-cancer early detection tests within the next two quarters, as a positive ruling for a rival would directly challenge Cologuard's screening dominance.
Nasdaq Jumps Nearly 500 Points On Iran Peace Deal Hopes: Investor Sentiment Improves, Greed Index Remains In ‘Fear’ Zone
Hopes of a peace deal with Iran have improved investor sentiment, leading to a significant jump in the Nasdaq, as tensions easing could reduce geopolitical risk and lead to increased market confidence.
Jun 22, 2026
Stocks Down Pre-Bell as Traders Assess US-Iran Deal Progress, Await Key Inflation Report
The progress in US-Iran deal talks has sparked hopes of easing geopolitical tensions, while traders await a key inflation report that could influence monetary policy decisions. This combination of events could significantly impact market sentiment and asset prices.
Jun 22, 2026
Stock Market Today: Dow Wavers Amid U.S.-Iran Peace Talks; SpaceX Stock Sells Off (Live Coverage)
The U.S. and Iran are engaging in peace talks, which could lead to a reduction in tensions and potentially impact markets. The outcome of these talks is being closely watched by investors, with the Dow wavering in response to the news.
Jun 22, 2026
Stock Market Today: Dow Rises Amid U.S.-Iran Peace Talks; SpaceX Stock Sells Off (Live Coverage)
The U.S. and Iran are engaging in peace talks, which could lead to a reduction in tensions and a decrease in geopolitical risk, and this development is supporting the stock market, including the Dow Jones index. The potential for de-escalation is a significant macro event that could impact various asset classes.
Jun 22, 2026
Earnings surprises
-316.9%
2026-02
+492.0%
2025-11
+1200.0%
2025-08
+43.2%
2025-05
+79.3%
2025-02
-7.2%
2024-11
The US has halted a planned military strike against Iran, easing tensions in the Middle East and potentially reducing the risk of conflict, which could positively impact global markets and asset classes.
US President Trump has halted a planned 'massive attack' on Iran, easing tensions and potentially avoiding a major conflict, which could positively impact global markets and reduce geopolitical risk.
The US has held off on striking Iran, leading to a gain in cryptocurrency prices, with analysts seeing a potential 'strong and vital move' in Bitcoin if the situation continues to de-escalate. This de-escalation could reduce geopolitical risk and increase investor appetite for riskier assets like cryptocurrencies.
The US has held off on striking Iran, leading to a gain in cryptocurrency prices, with analysts seeing a potential 'strong and vital move' in Bitcoin if the situation continues to de-escalate. This de-escalation could reduce geopolitical risk and increase investor appetite for riskier assets like cryptocurrencies.
Wall Street giants such as Goldman Sachs and BlackRock have endorsed the CLARITY Act, which aims to provide regulatory clarity for cryptocurrencies, potentially paving the way for increased institutional investment and adoption. This development could have significant implications for the crypto market and the broader financial sector.
Generated Sun, 28 Jun 2026 06:52:52 GMT by Decifer intelligence engine. For informational purposes only — not investment advice. Decifer Intelligence Hub.